Profound Medical Corp.
No SEC Form 4 filings for $PROF in the last 30 days.
See all $PROF insider activity →Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) said Matthew Sobczyk was promoted from Corporate Controller to Interim CFO, effective immediately, replacing Rashed Dewan, who stepped down as CFO and will stay on a short-term consulting contract. The company cited Sobczyk’s tenure since 2020 and aims to maintain continuity while executing its growth strategy for TULSA technology.
Profound Medical Corp. (PROF) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 exh_991.htm PRESS RELEASE EdgarFiling EXHIBIT 99.1 Profound Medical Reports Second Quarter 2026 Financial Results – Operating expenses decline 16%, helping drive a 39% improvement in net loss – – Approximately $3.1 million of TULSA revenue recognition shifts into early
Profound Medical Corp. (NASDAQ:PROF, TSX:PRN) will report its Q2 2026 financial results after market close on Aug. 6, 2026, and hold a conference call at 4:30 p.m. ET to discuss results and business updates, according to the company. The release also describes its iMRI platforms TULSA-PRO and Sonalleve and related regulatory clearances.
Over the past 7 days, alphai's AI scored 1 news story mentioning PROF (Profound Medical Corp.). Coverage has been balanced: 0 bullish, 1 neutral, and 0 bearish.
Recent PROF coverage spans financial news and earnings.
Management transition to an interim CFO can shift near-term financial oversight and investor confidence, but no guidance or financial metrics were provided.
The filing provides fresh operating metrics (revenue timing, margin, opex decline) plus continued guidance and payer coverage expansion, shaping near-term revenue recognition and sentiment.
This sets a specific earnings-event date and call time, creating a near-term catalyst for positioning and volatility expectations.
Conference and investor-session visibility for Profound’s TULSA-PRO platform, with no new clinical results or financial guidance disclosed in the text.
The SEC filing confirms the effectiveness of Profound Medical's S-3 Shelf Registration, which is a neutral event with minimal immediate market impact.
alphai scores every news story that mentions PROF with an AI model for sentiment and relevance, and aggregates insider trades from Profound Medical Corp.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) said Matthew Sobczyk was promoted from Corporate Controller to Interim CFO, effective immediately, replacing Rashed Dewan, who stepped down as CFO and will stay on a short-term consulting contract. The company cited Sobczyk’s tenure since 2020 and aims to maintain continuity while executing its growth strategy for TULSA technology.
2 min readProfound Medical Corp. (PROF) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 exh_991.htm PRESS RELEASE EdgarFiling EXHIBIT 99.1 Profound Medical Reports Second Quarter 2026 Financial Results – Operating expenses decline 16%, helping drive a 39% improvement in net loss – – Approximately $3.1 million of TULSA revenue recognition shifts into early
6 min readProfound Medical Corp. (NASDAQ:PROF, TSX:PRN) will report its Q2 2026 financial results after market close on Aug. 6, 2026, and hold a conference call at 4:30 p.m. ET to discuss results and business updates, according to the company. The release also describes its iMRI platforms TULSA-PRO and Sonalleve and related regulatory clearances.
2 min readProfound Medical Corp. (NASDAQ:PROF, TSX:PRN) said its MRI-guided, AI-powered TULSA-PRO incisionless prostate ablation will be featured at SRS2026 in Fort Lauderdale, July 23-26, with multiple physician presentations on registry and CAPTAIN trial outcomes. Profound also plans an investor session July 22 with Stifel and Wells Fargo analysts.
2 min readProfound Medical Corp. (NASDAQ: PROF) has announced an SEC Filing for Form EFFECT, indicating the effectiveness of its S-3 Shelf Registration Statement as of May 19, 2026, at 4:30 P.M. The filing shows a neutral impact and sentiment according to Rhea-AI. Profound Medical Corp. has a market cap of $250.37 million and is ranked #4372 by market capitalization.
2 min readProfound Medical (TSE:PRN) will showcase its TULSA-PRO platform at the 2026 Society of Interventional Radiology meeting, highlighting clinical outcomes and early results from their CAPTAIN trial. The company aims to position its incision-free, MRI-guided TULSA Procedure as a mainstream treatment for prostate disease, enhancing its competitive standing. Despite a "Hold" rating from analysts and financial challenges, the company seeks broader adoption through its focus on minimally invasive oncology.
3 min readRaymond James has reiterated an Outperform rating and an $11.00 price target for Profound Medical Corp. (NASDAQ:PROF) following strong 6-month data from its CAPTAIN trial. The firm anticipates similar robust 12-month outcomes, supporting the commercial momentum of the TULSA procedure. Despite a recent stock dip, the company shows significant revenue growth and is considered undervalued by InvestingPro, with analyst targets ranging from $11 to $13.
3 min readThis report provides risk-controlled trading plans for Profound Medical Corp. (PRN:CA) with specific buy and short targets and stop losses. It includes updated AI-generated signals and ratings for various terms (Near, Mid, Long) which are all currently "Weak." The article also lists an extensive archive of recent reports related to PRN:CA.
3 min readPRO FAMILIA Specialist Hospital in Poland, in collaboration with Profound Medical Corp., has completed its 500th Sonalleve® procedure, an MRI-guided, incision-free therapy for gynecologic conditions like uterine fibroids and adenomyosis. This achievement highlights the growing global adoption of Sonalleve as a non-surgical alternative, preserving fertility and offering faster recovery compared to traditional invasive surgeries. While Profound Medical prioritizes the U.S. commercialization of TULSA-PRO for prostate diseases, the international success of Sonalleve demonstrates the potential of its iMRI technology to treat a wider range of medical conditions without uterine removal.
4 min readProfound Medical (TSE:PRN) has upsized its private placement to secure US$6.45 million by issuing 921,428 common shares at US$7.00 each, driven by demand from an existing investor. The capital will fuel expansion in sales, marketing, working capital, R&D, potential strategic transactions, and general corporate purposes, reinforcing the company's financial standing as it commercializes its therapeutic platforms. Spark, TipRanks' AI Analyst, rates TSE:PRN as Neutral, highlighting strong revenue growth and strategic potential against operational inefficiencies and valuation concerns.
3 min read
